HER2 and tau expression as potential markers for response and survival to first line taxane plus cisplatin therapy in non-small cell lung cancer

Asia-Pacific Journal of Clinical Oncology

Volumn 5, Issue 4, 2009, Pages 232-241

  Shim, Byoung Yong ^a   Kim, Chi Hong ^a   Ahn, Myeong Im ^b   Kim, Sung Whan ^a   Cho, Deog Gon ^a   Cho, Kyo Do ^a   Yoo, Jinyoung ^c   Kim, Hoon Kyo ^a  

^a Department of Internal Medicine ^*  (South Korea)

^b The Catholic University of Korea   (South Korea)

^c The Catholic University of Korea   (South Korea)

Author keywords

Chromogenic in situ hybridization; Human epidermal growth factor receptor 2; Immunohistochemistry; Non small cell lung cancer; Tau

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; PROTEIN BCL 2; TAU PROTEIN; TAXANE DERIVATIVE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LARGE CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

EID: 71649101232     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2009.01244.x     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Schiller JH, Harrington D, Belani CP. Eastern Cooperative Oncology Group: comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-8.
3. Kelly K, Crowley J, Bunn PA. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001, 19:3210-18.
4. Cappuzzo F, Varella-Garcia M, Shigematsu H. Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients. J Clin Oncol 2005, 23:5007-18.
5. Lang K, Marciniak MD, Faries D. Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. Lung Cancer 2008, 63:264-70.
6. Ziółkowska-Seta I, Ma̧dry R, Kraszewska E. TP53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. Gynecol Oncol 2009, 112:179-84.
7. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000, 19:6550-65.
8. Xu JM, Han Y, Duan HQ. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. J Cancer Res Clin Oncol 2009, 135:771-82.
9. Hirsch FR, Varella-Garcia M, Franklin WA. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 2002, 86:1449-56.
10. Hirsch FR, Varella-Garcia M, Bunn PA. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003, 21:3798-807.
11. Singer CF, Gschwantler-Kaulich D, Fink-Retter A. HER2 overexpression and activation, and tamoxifen efficacy in receptor-positive early breast cancer. J Cancer Res Clin Oncol 2009, 135:807-13.
12. Emlet DR, Schwartz R, Brown KA, Pollice AA, Smith CA, Shackney SE. HER2 expression as a potential marker for response to therapy targeted to the EGFR. Br J Cancer 2006, 94:1144-53.
13. Papila C, Uzun H, Balci H. Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors. Med Oncol 2009, 26:151-6.
14. Pentheroudakis G, Kalogeras KT, Wirtz RM. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat 2008, 116:131-43.
15. Pusztai L. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents. Ann Oncol 2007, (12):xii15-20. Suppl.
16. Rouzier R, Rajan R, Wagner P. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci USA 2005, 102:8315-20.
17. Yaren A, Oztop I, Kargi A. Bax, bcl-2 and c-kit expression in non-small-cell lung cancer and their effects on prognosis. Int J Clin Pract 2006, 60:675-82.
18. Pritchard KI, Shepherd LE, O'Malley FP. National Cancer Institute of Canada Clinical Trials Group: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006, 354:2103-11.
19. Konecny GE, Thomssen C, Lück HJ. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004, 96:1141-51.
20. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998, 16:413-28.
21. Todorović-Raković N, Jovanović D, Nesković-Konstantinović Z, Nikolić-Vukosavljević D. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer. Exp Mol Pathol 2007, 82:262-8.
22. Perez-Soler R, Kemp B, Wu QP. Response and determinants of sensitivity to paclitaxel in human non-small cell lung cancer tumors heterotransplanted in nude mice. Clin Cancer Res 2000, 6:4932-8.
23. Cappuzzo F, Ligorio C, Toschi L. EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007, 2:423-9.
24. Pelosi G, Del Curto B, Dell'Orto P. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung. Int J Cancer 2005, 113:101-8.
25. Tan D, Deeb G, Wang J. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn Mol Pathol 2003, 12:201-11.
26. Brabender J, Danenberg KD, Metzger R. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001, 7:1850-5.
27. Tanner M, Gancberg D, Di Leo A. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000, 157:1467-72.
28. Dandachi N, Dietze O, Hauser-Kronberger C. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer. Anticancer Res 2004, 24:2401-6.
29. Joensuu H, Isola J, Lundin M. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003, 9:923-30.
30. Andre F, Hatzis C, Anderson K. Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer. Clin Cancer Res 2007, 13:2061-7.
31. Ferreira A, Caceres A. Estrogen-enhanced neurite growth: evidence for a selective induction of tau and stable microtubules. J Neurosci 1991, 11:392-400.
32. Tanaka S, Nohara T, Iwamoto M. Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer. Cancer Chemother Pharmacol 2009, 64:341-6. ahead of print
33. Mimori K, Sadanaga N, Yoshikawa Y. Reduced tau expression in gastric cancer can identify candidates for successful paclitaxel treatment. Br J Cancer 2006, 94:1894-7.
34. Dumontet C, Isaac S, Souquet PJ. Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy. Bull Cancer 2005, 92:E25-30.